Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.
December 20, 2024

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest and land in Latvia

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of 100% of the shares in the two Latvian companies SIA "Latvijas Mežu Aģentūra" and SIA "Vadakstes Meži" (the “Companies") from Skogsfond Baltikum AB (publ). The Companies own a total of 8,080 hectares of forest and land in Latvia.
December 16, 2024

Vinge assists enterstore in connection with the acquisition of Miss Mary of Sweden

Enterstore a.s., owned by Hartenberg Holding, has entered into an agreement with Scope Growth III L.P. to acquire Swedish Bra Holding AB, Miss Mary of Sweden. Miss Mary is engaged in the design, manufacture, and sale of women's underwear, with approximately 90 percent of its revenue coming from e-commerce. enterstore is an e-commerce group consisting of portfolio companies with leading brands in niche industries.
December 16, 2024